Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Mar;63(3):420–423. doi: 10.1038/bjc.1991.97

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.

N W Clarke 1, I B Holbrook 1, J McClure 1, N J George 1
PMCID: PMC1971879  PMID: 2003984

Abstract

Twenty five hormone manipulated patients with prostate cancer and metastatic bone disease, treated at least 6/12 previously by hormone manipulation, were given intravenous infusions of Disodium Pamidronate (APD) over a 6 month period. Patients received 30 mg weekly for 4 weeks then twice monthly for 5 months. No other treatment was administered during study. Eleven of 17 patients with pain at the start of the study were pain free at the end. Fasting morning calcium excretion and serum osteocalcin fell significantly with Pamidronate (P less than 0.0001) and urine hydroxyproline was lowered in 13/20 evaluable patients at 6 months. Alkaline phosphatase fell in a proportion of patients and five of 17 patients with previously progressive bone scans stabilised (4) or regressed (1) on treatment. Rising acid phosphatase levels were also lowered in five patients. It is concluded that Pamidronate may be effective in palliating bone pain in some patients and has a stabilising influence on abnormally high bone turnover in metastatic prostate cancer. Further controlled studies of the compound are now warranted.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABRAMS H. L., SPIRO R., GOLDSTEIN N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950 Jan;3(1):74–85. doi: 10.1002/1097-0142(1950)3:1<74::aid-cncr2820030111>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  2. Adami S., Salvagno G., Guarrera G., Bianchi G., Dorizzi R., Rosini S., Mobilio G., Lo Cascio V. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985 Dec;134(6):1152–1154. doi: 10.1016/s0022-5347(17)47663-4. [DOI] [PubMed] [Google Scholar]
  3. Galasko C. S. Mechanisms of bone destruction in the development of skeletal metastases. Nature. 1976 Oct 7;263(5577):507–508. doi: 10.1038/263507a0. [DOI] [PubMed] [Google Scholar]
  4. Labasky R. F., Smith J. A., Jr Management of pain and other symptoms of advanced prostatic cancer. Semin Urol. 1988 Nov;6(4):311–321. [PubMed] [Google Scholar]
  5. Masud T., Slevin M. L. Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma. Lancet. 1989 May 6;1(8645):1021–1022. doi: 10.1016/s0140-6736(89)92665-2. [DOI] [PubMed] [Google Scholar]
  6. Morton A. R., Cantrill J. A., Pillai G. V., McMahon A., Anderson D. C., Howell A. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ. 1988 Sep 24;297(6651):772–773. doi: 10.1136/bmj.297.6651.772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Morton A. R., Howell A. Bisphosphonates and bone metastases. Br J Cancer. 1988 Nov;58(5):556–557. doi: 10.1038/bjc.1988.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Percival R. C., Urwin G. H., Harris S., Yates A. J., Williams J. L., Beneton M., Kanis J. A. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 1987 Feb;13(1):41–49. [PubMed] [Google Scholar]
  9. Reitsma P. H., Bijvoet O. L., Potokar M., van der Wee-Pals L. J., van Wijk-van Lennep M. M. Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Calcif Tissue Int. 1983 May;35(3):357–361. doi: 10.1007/BF02405058. [DOI] [PubMed] [Google Scholar]
  10. Sleeboom H. P., Bijvoet O. L., van Oosterom A. T., Gleed J. H., O'Riordan J. L. Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet. 1983 Jul 30;2(8344):239–243. doi: 10.1016/s0140-6736(83)90231-3. [DOI] [PubMed] [Google Scholar]
  11. Urwin G. H., Percival R. C., Harris S., Beneton M. N., Williams J. L., Kanis J. A. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 1985 Dec;57(6):721–723. doi: 10.1111/j.1464-410x.1985.tb07040.x. [DOI] [PubMed] [Google Scholar]
  12. Waxman J. Hormonal aspects of prostatic cancer: a review. J R Soc Med. 1985 Feb;78(2):129–135. doi: 10.1177/014107688507800212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. van Holten-Verzantvoort A. T., Bijvoet O. L., Cleton F. J., Hermans J., Kroon H. M., Harinck H. I., Vermey P., Elte J. W., Neijt J. P., Beex L. V. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987 Oct 31;2(8566):983–985. doi: 10.1016/s0140-6736(87)92555-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES